Associate Scientific Director
Bristol-Myers Squibb Company
Deepak Bahl, Ph.D., Associate Scientific Director, Bristol-Myers Squibb Company
Deepak Bahl currently serves as an Associate Director at the Bristol-Myers Squibb (BMS). He has over 18 years of experience in developing conventional and enabled dosage forms of small molecules, liquids, parenterals, and peptides. Prior to BMS, he held positions of increased responsibilities at Celgene, Merck and Co., Catalent Pharma Solutions, and Ranbaxy Research Laboratories.
Deepak has a Ph.D. in Pharmaceutical Sciences from the University of Connecticut, CT and Masters in Pharmacy (M. Pharm) from the College of Pharmacy, New Delhi. His work has led to the approval of four NDAs & MAAs, five ANDAs, three 505(B)(2)s, one BLA, and several patents/publications. His expertise includes design and scale up of complex formulations such as gastroretentive systems (GR), controlled release, multilayer tablets including bilayer and trilayer tablets, Zydis® orally disintegrating tablets, multi-unit dosage units (MUPS), and reverse engineering for development of generic bioequivalent pharmaceutical products. Deepak has held several leadership positions at the American Association of Pharmaceutical Scientists (AAPS) and currently serves as the chair of the AAPS Preformulation & Formulaton Design/Development Community.